WO1998016629A1 - Defined systems for epithelial cell culture and use thereof - Google Patents
Defined systems for epithelial cell culture and use thereof Download PDFInfo
- Publication number
- WO1998016629A1 WO1998016629A1 PCT/US1997/018260 US9718260W WO9816629A1 WO 1998016629 A1 WO1998016629 A1 WO 1998016629A1 US 9718260 W US9718260 W US 9718260W WO 9816629 A1 WO9816629 A1 WO 9816629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- medium
- composition
- camp
- salt
- Prior art date
Links
- 210000002919 epithelial cell Anatomy 0.000 title claims abstract description 67
- 238000004113 cell culture Methods 0.000 title abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 119
- 238000009472 formulation Methods 0.000 claims abstract description 72
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 66
- 239000006143 cell culture medium Substances 0.000 claims abstract description 54
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 54
- 239000001963 growth medium Substances 0.000 claims abstract description 46
- 241001465754 Metazoa Species 0.000 claims abstract description 45
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims abstract description 40
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims abstract description 40
- 229940126864 fibroblast growth factor Drugs 0.000 claims abstract description 40
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 33
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 31
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 31
- 238000000338 in vitro Methods 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 28
- 210000004102 animal cell Anatomy 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 22
- 210000000056 organ Anatomy 0.000 claims abstract description 20
- 210000004907 gland Anatomy 0.000 claims abstract description 17
- 230000003834 intracellular effect Effects 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 158
- 239000002609 medium Substances 0.000 claims description 117
- 210000002510 keratinocyte Anatomy 0.000 claims description 100
- 239000004615 ingredient Substances 0.000 claims description 58
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 41
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 36
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 32
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 29
- 239000007640 basal medium Substances 0.000 claims description 29
- 229940116977 epidermal growth factor Drugs 0.000 claims description 29
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 28
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 28
- 229960002897 heparin Drugs 0.000 claims description 28
- 229920000669 heparin Polymers 0.000 claims description 28
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 24
- 229940039009 isoproterenol Drugs 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 22
- 230000037041 intracellular level Effects 0.000 claims description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 18
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 16
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 13
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 11
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 10
- 108090001061 Insulin Proteins 0.000 claims description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 229940125396 insulin Drugs 0.000 claims description 10
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 9
- 229960000890 hydrocortisone Drugs 0.000 claims description 9
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000008093 supporting effect Effects 0.000 claims description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 8
- -1 z'-inositol Substances 0.000 claims description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 7
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 7
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- 229960005261 aspartic acid Drugs 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 7
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical group O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 6
- 229930064664 L-arginine Natural products 0.000 claims description 6
- 235000014852 L-arginine Nutrition 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 6
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 5
- 102000009016 Cholera Toxin Human genes 0.000 claims description 5
- 108010049048 Cholera Toxin Proteins 0.000 claims description 5
- 235000019743 Choline chloride Nutrition 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- 239000007995 HEPES buffer Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- 239000004395 L-leucine Substances 0.000 claims description 5
- 235000019454 L-leucine Nutrition 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930195722 L-methionine Natural products 0.000 claims description 5
- 229930182821 L-proline Natural products 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 5
- 239000005700 Putrescine Substances 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 5
- 102000004338 Transferrin Human genes 0.000 claims description 5
- 108090000901 Transferrin Proteins 0.000 claims description 5
- 229960003767 alanine Drugs 0.000 claims description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 210000000424 bronchial epithelial cell Anatomy 0.000 claims description 5
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 claims description 5
- 229960005263 bucladesine Drugs 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 5
- 229960003178 choline chloride Drugs 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- 229960000367 inositol Drugs 0.000 claims description 5
- 229960003136 leucine Drugs 0.000 claims description 5
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 5
- 235000019136 lipoic acid Nutrition 0.000 claims description 5
- 229960004452 methionine Drugs 0.000 claims description 5
- 229960003966 nicotinamide Drugs 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- 229940014662 pantothenate Drugs 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 5
- 229960002429 proline Drugs 0.000 claims description 5
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 235000019192 riboflavin Nutrition 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 239000002151 riboflavin Substances 0.000 claims description 5
- 229960001153 serine Drugs 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 229940054269 sodium pyruvate Drugs 0.000 claims description 5
- 235000019157 thiamine Nutrition 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- 239000011721 thiamine Substances 0.000 claims description 5
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 5
- 229960002663 thioctic acid Drugs 0.000 claims description 5
- 229960002898 threonine Drugs 0.000 claims description 5
- 229940104230 thymidine Drugs 0.000 claims description 5
- 239000012581 transferrin Substances 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 4
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 4
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 claims description 4
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 claims description 4
- 229930024421 Adenine Natural products 0.000 claims description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 4
- 108091006027 G proteins Proteins 0.000 claims description 4
- 102000030782 GTP binding Human genes 0.000 claims description 4
- 108091000058 GTP-Binding Proteins 0.000 claims description 4
- 229930182816 L-glutamine Natural products 0.000 claims description 4
- 229930182844 L-isoleucine Natural products 0.000 claims description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 4
- 229910000366 copper(II) sulfate Inorganic materials 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 229960002449 glycine Drugs 0.000 claims description 4
- 229960002885 histidine Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 150000002696 manganese Chemical class 0.000 claims description 4
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 4
- 229960000278 theophylline Drugs 0.000 claims description 4
- 229960004441 tyrosine Drugs 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 239000007832 Na2SO4 Substances 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940031098 ethanolamine Drugs 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 3
- 229960002743 glutamine Drugs 0.000 claims 3
- 210000005260 human cell Anatomy 0.000 claims 3
- 150000002751 molybdenum Chemical class 0.000 claims 3
- 150000002815 nickel Chemical class 0.000 claims 3
- 125000003748 selenium group Chemical class *[Se]* 0.000 claims 3
- 150000003681 vanadium Chemical class 0.000 claims 3
- 150000003751 zinc Chemical class 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims 2
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 description 45
- 230000012010 growth Effects 0.000 description 43
- 239000000243 solution Substances 0.000 description 35
- 102400001368 Epidermal growth factor Human genes 0.000 description 27
- 239000000306 component Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 239000013589 supplement Substances 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000011550 stock solution Substances 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 210000004789 organ system Anatomy 0.000 description 6
- 235000013619 trace mineral Nutrition 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003953 foreskin Anatomy 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000012154 double-distilled water Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229910019626 (NH4)6Mo7O24 Inorganic materials 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 3
- 108010066321 Keratin-14 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 3
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 3
- 229910003206 NH4VO3 Inorganic materials 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011565 manganese chloride Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012533 medium component Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Chemical group 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000010370 cell cloning Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 2
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 239000011686 zinc sulphate Substances 0.000 description 2
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- 101100395863 Caenorhabditis elegans hst-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101150101014 HST1 gene Proteins 0.000 description 1
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- JWZZKOKVBUJMES-NSHDSACASA-N L-isoprenaline Chemical compound CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-NSHDSACASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- ASIYFCYUCMQNGK-JZGIKJSDSA-L disodium L-tyrosinate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC1=CC=C([O-])C=C1 ASIYFCYUCMQNGK-JZGIKJSDSA-L 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003861 general physiology Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 229950008384 levisoprenaline Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0025—Culture media for plant cell or plant tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/81—Adrenaline
Definitions
- the present invention relates generally to cell culture medium formulations. Specifically, the present invention provides systems comprising defined cell culture medium formulations that facilitate the in vitro cultivation of epithelial cells, particularly keratinocytes. The present invention also provides methods for cultivation of animal cells using these systems.
- Cell culture media provide the nutrients necessary to maintain and grow cells in a controlled, artificial and in vitro environment. Characteristics and compositions of the cell culture media vary depending on the particular cellular requirements. Important parameters include osmolarity, pH, and nutrient formulations. Media formulations have been used to cultivate a number of cell types including animal, plant and bacterial cells. Cells cultivated in culture media catabolize available nutrients and produce useful biological substances such as monoclonal antibodies, hormones, growth factors and the like. Such products have therapeutic applications and, with the advent of recombinant DNA technology, cells can be engineered to produce large quantities of these products. Thus, the ability to cultivate cells in vitro is not only important for the study of cell physiology, but is also necessary for the production of useful substances which may not otherwise be obtained by cost-effective means.
- Typical components of cell culture media include amino acids, organic and inorganic salts, vitamins, trace metals, sugars, lipids and nucleic acids, the types and amounts of which may vary depending upon the particular requirements of a given cell or tissue type.
- cell culture media formulations are supplemented with a range of additives, including undefined components such as fetal bovine serum (FBS) (10-20% v/v) or extracts from animal embryos, organs or glands (0.5-10% v/v). While FBS is the most commonly applied supplement in animal cell culture media, other serum sources are also routinely used, including newborn calf, horse and human. Organs or glands that have been used to prepare extracts for the supplementation of culture media include submaxillary gland (Cohen, S., J. Biol. Chem.
- these supplements provide carriers or chelators for labile or water-insoluble nutrients; bind and neutralize toxic moieties; provide hormones and growth factors, protease inhibitors and essential, often unidentified or undefined low molecular weight nutrients; and protect cells from physical stress and damage.
- serum or organ/gland extracts are commonly used as relatively low-cost supplements to provide an optimal culture medium for the cultivation of animal cells.
- the use of serum or organ/gland extracts in tissue culture applications has several drawbacks (Lambert, K.J. etal, In: Animal Cell Biotechnology, Vol 1, Spier, R.E. et al, Eds., Academic Pres New York, pp. 85-122 (1985)).
- defined culture media Often used interchangeably with “defined culture media” is the term “serum-free media” or "SFM.”
- SFM serum-free media
- a number of SFM formulations are commercially available, such as those designed to support the culture of endothelial cells, keratinocytes, monocytes/macrophages, fibroblasts, chondrocytes or hepatocytes which are available from GIBCO/LTI (Gaithersburg, Maryland).
- SFM serum-free media
- SFM serum-free media
- defined media generally provide several distinct advantages to the user. For example, the use of defined media facilitates the investigation of the effects of a specific growth factor or other medium component on cellular physiology, which may be masked when the cells are cultivated in serum- or extract-containing media.
- defined media typically contain much lower quantities of protein (indeed, defined media are often termed "low protein media") than those containing serum or extracts, rendering purification of biological substances produced by cells cultured in defined media far simpler and more cost-effective.
- basal media Some extremely simple defined media, which consist essentially of vitamins, amino acids, organic and inorganic salts and buffers have been used for cell culture. Such media (often called “basal media”), however, are usually seriously deficient in the nutritional content required by most animal cells. Accordingly, most defined media incorporate into the basal media additional components to make the media more nutritionally complex, but to maintain the serum-free and low protein content of the media.
- Such components include serum albumin from bovine (BSA) or human (HSA); certain growth factors derived from natural (animal) or recombinant sources such as EGF or FGF; lipids such as fatty acids, sterols and phospholipids; lipid derivatives and complexes such as phosphoethanolamine, ethanolamine and lipoproteins; protein and steroid hormones such as insulin, hydrocortisone and progesterone; nucleotide precursors; and certain trace elements (reviewed by Waymouth, C, in: Cell Culture Methods for Molecular and Cell Biology, Vol.
- BSA bovine
- HSA human
- growth factors derived from natural (animal) or recombinant sources such as EGF or FGF
- lipids such as fatty acids, sterols and phospholipids
- lipid derivatives and complexes such as phosphoethanolamine, ethanolamine and lipoproteins
- protein and steroid hormones such as insulin, hydrocortisone and progesterone
- the epithelium lines the internal and external surfaces of the organs and glands of higher organisms. Because of this localization at the external interface between the environment and the organism (e.g., the skin) or at the internal interface between an organ and the interstitial space (e.g., the intestinal mucosal lining), the epithelium has a major role in the maintenance of homeostasis.
- the epithelium carries out this function, for example, by regulating transport and permeability of nutrients and wastes (Freshney, R.I., in: Culture of Epithelial Cells, Freshney, R.I., ed., New York: Wiley-Liss, pp. 1-23 (1992)).
- epithelial cells The cells making up the epithelium are generically termed epithelial cells. These cells may be present in multiple layers as in the skin, or in a single layer as in the lung alveoli. As might be expected, the structure, function and physiology of epithelial cells are often tissue-specific. For example, the epidermal epithelial cells of the skin are organized as stratified squamous epithelium and are primarily involved in forming a protective barrier for the organism, while the secretory epithelial cells of many glands are often found in single layers of cuboidal cells that have a major role in producing secretory proteins and glycoproteins. Regardless of their location or function, however, epithelial cells are usually regenerative.
- epithelial cells are capable of dividing or growing. This regenerative capacity has facilitated the in vitro manipulation of epithelial cells, to the point where a variety of primary epithelial cells and cell lines have been successfully cultivated in vitro (Freshney, Id.). Keratinocytes
- the specialized epithelial cells found in the epidermis of the skin are known as keratinocytes.
- keratinocytes The specialized epithelial cells found in the epidermis of the skin are known as keratinocytes.
- the cytoplasm of the keratinocytes is completely replaced with keratin and the cells are dead.
- the keratinocytes located in the lower layers however, particularly in the basal epidermis (stratum basale), actively divide and ultimately migrate up through the more superficial layers to replace those cells being sloughed off at the external surface.
- the skin can be thought of as a dynamic organ comprising keratinocytes that are constantly dividing, maturing and ultimately dying.
- One of the first serum-free medium formulations developed for keratinocyte culture was based on Medium 199 and included a growth factor cocktail comprising bovine brain extract (Gilchrest, B.A., et al, J. Cell. Physiol. 112:197 (1982)), and serum-free culture of human keratinocytes without the use of 3T3 fibroblast feeder layers became widely accepted upon the development of a more specialized basal medium, MCDB-153 (Boyce, S.T., and Ham, R.G., J. Invest. Dermatol. 57:33 (1983); U.S. Patent Nos. 4,673,649 and 4,940,666).
- Serum-free MCDB-153 includes trace elements, ethanolamine, phosphoethanolamine, hydrocortisone, EGF, and bovine pituitary extract (BPE). This medium and several enhanced versions have been used widely for human keratinocyte cultivation (Pittelkow, M.R., and Scott, R.E., Mayo Clin. Proc. 67:771 (1986); Pirisi, L., et al, J. Virol. 67: 1061 (1987); Shipley, G.D., and Pittelkow, M.R., Arch. Dermatol. 723: 1541 (1987); Daley, IP., et al, FOCUS (GIBCO/LTI) 12:68 (1990)).
- culture media that are serum- and organ/gland extract- free, for the cultivation of animal epithelial cells including keratinocytes.
- Such culture media will facilitate studies of the effects of growth factors and other stimuli on cellular physiology, will allow easier and more cost-effective purification of biological substances produced by cultured animal cells in the biotechnology industry, and will provide more consistent results in methods employing the cultivation of animal epithelial cells.
- the current invention provides such defined media.
- the present invention provides defined culture media that replace BPE with growth- promoting additives such as insulin, EGF and other additives.
- the invention provides a cell culture medium, capable of supporting the cultivation of an animal epithelial cell in vitro, comprising insulin, EGF, and at least two additional additives from the group consisting of FGF, an agent that increases intracellular levels of cyclic adenosine monophosphate (cAMP) and ascorbic acid.
- the medium provided by the present invention may be a IX formulation, or may be concentrated as a 1 OX or higher formulation.
- the present invention also provides methods of culturing animal epithelial cells using the culture medium formulations disclosed herein, comprising the steps of (a) contacting an animal cell with the cell culture medium of the present invention; and (b) cultivating the animal cell under conditions suitable to support its cultivation in vitro.
- the invention also provides kits for use in the cultivation of an animal epithelial cell.
- the invention also provides compositions comprising heparin, EGF, FGF, at least one agent that increases intracellular levels of cAMP, and optionally ascorbic acid, which compositions may be used to replace organ or gland extracts in serum-free animal cell culture media.
- the culture media of the present invention are suitable for use in the isolation and initiation of primary epithelial cell cultures, as well as for the expansion of established epithelial cell cultures. Additionally, the media of the present invention provide superior growth, and maintenance of morphological and physiological markers, of primary animal epithelial cells.
- FIG. 1 Photomicrographs of phase contrast microscopy of human keratinocytes. Cells were cultured in the defined keratinocyte SFM of the present invention (panel A) or in a BPE- containing keratinocyte SFM (panel B). Photographs are 100X.
- FIG. 1 Photomicrograph of fluorescence microscopy of human keratinocytes cultured in the defined keratinocyte SFM of the present invention and stained with fluorescent antibodies directed against keratin 14.
- Figure 5 Bar graph demonstrating growth kinetic analysis of human keratinocytes.
- Figure 6 Line graph demonstrating an evaluation of media shelf life using primary human keratinocytes.
- Cells were cultured in the defined keratinocyte SFM of the present invention (solid line) or in a BPE-containing keratinocyte SFM (dashed line) over a 15-week period. Cells were counted after 6 days in medium stored for given times and compared to control cells cultured in fresh medium.
- cell culture or “culture” is meant the maintenance of cells in an artificial, in vitro environment. It is to be understood, however, that the term “cell culture” is a generic term and may be used to encompass the cultivation not only of individual cells, but also of tissues, organs, organ systems or whole organisms, for which the terms “tissue culture,” “organ culture,” “organ system culture” or “organotypic culture” may occasionally be used interchangeably with the term “cell culture.”
- cultivation is meant the maintenance of cells in vitro under conditions favoring growth, differentiation or continued viability, in an active or quiescent state, of the cells.
- cultivation may be used interchangeably with “cell culture” or any of its synonyms described above.
- culture vessel is meant a glass, plastic, or metal container that can provide an aseptic environment for culturing cells.
- cell culture medium By “cell culture medium,” “culture medium” (plural “media” in each case) and
- medium formulation refer to a nutritive solution for cultivating cells and may be used interchangeably.
- contacting refers to the placing of cells to be cultivated in vitro into a culture vessel with the medium in which the cells are to be cultivated.
- the term “contacting” encompasses mixing cells with medium, pipetting medium onto cells in a culture vessel, and submerging cells in culture medium.
- a cell culture medium is composed of a number of ingredients and these ingredients vary from one culture medium to another.
- a "IX formulation” is meant to refer to any aqueous solution that contains some or all ingredients found in a cell culture medium at working concentrations.
- the "IX formulation” can refer to, for example, the cell culture medium or to any subgroup of ingredients for that medium.
- the concentration of an ingredient in a IX solution is about the same as the concentration of that ingredient found in a cell culture formulation used for maintaining or cultivating cells in vitro.
- a cell culture medium used for the in vitro cultivation of cells is a IX formulation by definition. When a number of ingredients are present, each ingredient in a IX formulation has a concentration about equal to the concentration of those ingredients in a cell culture medium.
- RPMI-1640 culture medium contains, among other ingredients, 0.2 g/L L-arginine, 0.05 g/L L-asparagine, and 0.02 g/L L-aspartic acid.
- a " IX formulation" of these amino acids contains about the same concentrations of these ingredients in solution.
- each ingredient in solution has the same or about the same concentration as that found in the cell culture medium being described.
- concentrations of ingredients in a IX formulation of cell culture medium are well known to those of ordinary skill in the art. See Methods For Preparation of Media, Supplements and Substrate For Serum-Free Animal Cell Culture Allen R. Liss, N.Y.
- a 10X formulation is meant to refer to a solution wherein each ingredient in that solution is about 10 times more concentrated than the same ingredient in the cell culture medium.
- a 10X formulation of RPMT-1640 culture medium may contain, among other ingredients, 2.0 g L L-arginine, 0.5 g/L L-asparagine, and 0.2 g/L L-aspartic acid (compare IX formulation, above).
- a “10X formulation” may contain a number of additional ingredients at a concentration about 10 times that found in the IX culture medium.
- “25X formulation,” “5 OX formulation,” “100X formulation,” “ 500X formulation,” and “1000X formulation” designate solutions that contain ingredients at about 25-, 50-, 100-, 500-, or 1000- fold concentrations, respectively, as compared to a IX cell culture medium. Again, the osmolarity and pH of the media formulation and concentrated solution may vary.
- the cell culture media of the present invention are aqueous-based, comprising a number of ingredients in a solution of deionized, distilled water to form "basal media.”
- Ingredients which the basal media of the present invention may include are amino acids, vitamins, inorganic salts, adenine, ethanolamine, D-glucose, heparin, N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] (HEPES), hydrocortisone, insulin, lipoic acid, phenol red, phosphoethanolamine, putrescine, sodium pyruvate, triiodothyronine (T3), thymidine and transferrin.
- insulin and transferrin may be replaced by ferric citrate or ferrous sulfate chelates.
- Each of these ingredients may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
- Amino acid ingredients which may be included in the media of the present invention include L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L- glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine and L-valine. These amino acids may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
- Vitamin ingredients which may be included in the media of the present invention include biotin, choline chloride, D-Ca ++ -pantothenate, folic acid, 7-inositol, niacinamide, pyridoxine, riboflavin, thiamine and vitamin B 12 . These vitamins may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
- Inorganic salt ingredients which may be used in the media of the present invention include a calcium salt (e.g., CaCl 2 ), CuSO 4 , FeSO 4 , KC1, a magnesium salt (e.g., MgCl j ), a manganese salt (e.g., MnCl 2 ), Sodium acetate, NaCl, NaHCO 3 , Na 2 HPO 4 , Na ⁇ O ⁇ and ions of the trace elements selenium, silicon, molybdenum, vanadium, nickel, tin and zinc.
- a calcium salt e.g., CaCl 2
- CuSO 4 , FeSO 4 , KC1
- MgCl j magnesium salt
- MnCl 2 manganese salt
- Sodium acetate, NaCl, NaHCO 3 , Na 2 HPO 4 , Na ⁇ O ⁇ and ions of the trace elements selenium, silicon, molybdenum, vanadium, nickel, tin and zinc.
- trace elements may be provided in a variety of forms, preferably in the form of salts such as Na j SeO j , Na ⁇ iO j , (NH 4 )6Mo 7 O 24 , NH 4 VO 3 , NiSO 4 , SnCl and ZnSO.
- salts such as Na j SeO j , Na ⁇ iO j , (NH 4 )6Mo 7 O 24 , NH 4 VO 3 , NiSO 4 , SnCl and ZnSO.
- These inorganic salts and trace elements may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
- heparin epidermal growth factor
- cAMP cyclic adenosine monophosphate
- FGF fibroblast growth factor
- Heparin, EGF, the cAMP-increasing agent(s) and FGF(s) may be added to freshly formulated basal medium, or they may be admixed as described in detail in Example 1 in a solution of Dulbecco's Phosphate Buffered Saline (DPBS) and stored frozen, preferably at about -20 °C to about -70 °C, until being added to basal medium to formulate the complete medium of the present invention.
- DPBS Dulbecco's Phosphate Buffered Saline
- This admixture of heparin, EGF, the cAMP-increasing agent(s) and FGF(s) may be used as a replacement for BPE or other organ/gland extracts in animal cell culture media.
- the admixture may also be prepared as a 1X-1000X formulation, most preferably as a IX, 100X, 500X or 1000X formulation, which is then diluted appropriately into culture medium to provide a IX final formulation in the complete media of the present invention as described in detail in Example 1.
- Heparin may be obtained commercially, for example from Sigma (Saint Louis, Missouri), and is preferably derived from porcine mucosa. Heparin is added to the present media primarily to stabilize the activity of the growth factor components, especially FGF (Gospodarowicz, D., and Cheng, I, J. Cell. Physiol. 725:475-484 (1986); EP 0408 146). To formulate the medium of the present invention, heparin is added to the basal medium shown in Table 1 at a concentration of about 1-500 U.S.P. units/liter, preferably about 5-50 U.S.P. units/liter, and most preferably about 10 U.S.P. units/liter.
- EGF may be natural or recombinant and may be human or rodent. EGF is available commercially (e.g., from GIBCO/LTI, Gaithersburg, Maryland), or may be isolated from natural sources or produced by recombinant DNA techniques (U.S. Patent No. 4,743,679) according to methodologies that are routine in the art.
- EGF should be added to the basal medium shown in Table 1 at a concentration of about 0.00001-10 mg/L, preferably about 0.0001-0.1 mg/L, and most preferably about 0.0002 mg/L.
- a variety of agents that increase intracellular cAMP levels may be used in formulating the media of the present invention.
- agents which induce a direct increase in intracellular cAMP levels e.g., dibutyryl cAMP
- agents which cause an increase in intracellular cAMP levels by an interaction with a cellular G-protein e.g., cholera toxin and forskolin
- agents which cause an increase in intracellular cAMP levels by acting as agonists of ⁇ -adrenergic receptors e.g., isoproterenol
- agents which cause an increase in intracellular cAMP levels by inhibiting the activities of cAMP phosphodiesterases e.g., isobutylmethylxanthine (IBMX) and theophylline).
- isoproterenol Most preferable for use in formulating the media of the present invention is isoproterenol.
- cAMP-increasing agents are available commercially, e.g. from Sigma (St. Louis, Missouri), and are used at concentrations approximating those described in Green (Proc. Natl. Acad. Sci. USA 75:801-811 (1978)).
- cholera toxin is added to the basal medium described above at a concentration of about 0.000005-1 mg/L, preferably about 0.0007-0.1 mg/L, and most preferably about 0.08 mg/L.
- Dibutyryl cAMP is added to the basal media at a concentration of about 25-750 mg/L, preferably about 45-500 mg/L, and most preferably about 148 mg/L.
- IBMX may be added to the basal media at a concentration of about 0.2-25 mg L, preferably about 2-10 mg/L, and most preferably about 7 mg/L.
- isoproterenol is the agent used to increase intracellular cAMP levels, and is formulated into the basal media at a concentration of about 0.01-10 mg/L, preferably about 0.1-5 mg/L, and most preferably about 0.25 mg/L
- the FGF used in formulating the media of the present invention may be any member of the FGF family of growth factors, including FGF-1 (acidic FGF or aFGF), FGF-2 (basic FGF or bFGF), FGF-3 (int-2), FGF-4 (K-FGF), FGF-5 (hst-1), FGF-6 (hst-2) and FGF-7 (keratinocyte growth factor or KGF).
- FGF-1 acidic FGF or aFGF
- FGF-2 basic FGF or bFGF
- FGF-3 int-2
- FGF-4 K-FGF
- FGF-5 hst-1
- FGF-6 hst-2
- FGF-7 keratinocyte growth factor or KGF
- aFGF bFGF
- Natural or recombinant FGF may be used, which may be of human, bovine, porcine or rodent origin. Most preferably, recombinant human aFGF is used in formulating the present media.
- aFGF, bFGF and KGF are available commercially (e.g., from GIBCO/LTI, Gaithersburg, Maryland and R&D Systems, Inc., Minneapolis, Minnesota), or may be isolated from natural sources or produced by recombinant DNA techniques (EP 0 408 146 and U.S. Patent No. 5,395,756 for aFGF; U.S. Patent No. 5,189,148 for bFGF; WO 90/08771 and WO 95/01434 for KGF) according to methodologies that are routine in the art.
- FGF should be added to the basal medium shown in Table 1 at a concentration of about 0.0001-10 mg/L, preferably about 0.001-0.1 mg/L, and most preferably about 0.005 mg/L.
- the basal medium, heparin, EGF, cAMP-increasing agent(s) and FGF(s) formulate complete culture media according to the present invention.
- These complete media are suitable for use in the culture of a variety of animal epithelial cells, as described in more detail below. It may be preferable, however, to further enrich the nutritional content of the complete media to support faster growth and enhanced production of biologicals by the cultured cells, and to provide a more suitable environment for the culture of fastidious animal epithelial cells.
- ascorbic acid may be added to the complete media. Ascorbic acid is available commercially in several forms.
- Preferable for use in formulating the present media is L-ascorbic acid phosphate, magnesium salt, available from Wako Pure Chemical Industries, which is added to the media at a concentration of about 0.001-10 mg/L, preferably about 0.01-5 mg/L, and most preferably about 0.1 mg/L.
- the medium ingredients can be dissolved in a liquid carrier or maintained in dry form. If dissolved in a liquid carrier at the preferred concentrations shown in Table 1 (i.e., a "IX formulation"), the pH of the medium should be adjusted to about 7.0-7.6, preferably about 7.1- 7.5, and most preferably about 7.2-7.4.
- the osmolarity of the medium should also be adjusted to about 275-350 mOsm, preferably about 285-325 mOsm, and most preferably about 280-310 mOsm.
- the type of liquid carrier and the method used to dissolve the ingredients into solution vary and can be determined by one of ordinary skill in the art with no more than routine experimentation. Typically, the medium ingredients can be added in any order.
- the solutions comprising ingredients are more concentrated than the concentration of the same ingredients in a IX media formulation.
- the ingredients can be 10-fold more concentrated (10X formulation), 25-fold more concentrated (25X formulation), 50-fold more concentrated (50X concentration), or 100-fold more concentrated (100X formulation). More highly concentrated formulations can be made, provided that the ingredients remain soluble and stable. See U.S. Patent No. 5,474,931, which is directed to methods of solubilizing culture media components at high concentrations. If the media ingredients are prepared as separate concentrated solutions, an appropriate (sufficient) amount of each concentrate is combined with a diluent to produce a IX medium formulation.
- the diluent used is water but other solutions including aqueous buffers, aqueous saline solution, or other aqueous solutions may be used according to the invention.
- the culture media of the present invention are typically sterilized to prevent unwanted contamination. Sterilization may be accomplished, for example, by filtration through a low protein-binding membrane filter of about 0.1-1.0 ⁇ m pore size (available commercially, for example, from Millipore, Bedford, Massachusetts) after admixing the concentrated ingredients to produce a sterile culture medium. Alternatively, concentrated subgroups of ingredients may be filter-sterilized and stored as sterile solutions.
- sterile concentrates can then be mixed under aseptic conditions with a sterile diluent to produce a concentrated IX sterile medium formulation.
- Autoclaving or other elevated temperature-based methods of sterilization are not favored, since many of the components of the present culture media are heat labile and will be irreversibly degraded by temperatures such as those achieved during most heat sterilization methods.
- the optimal concentration ranges for the basal medium ingredients are listed in Table 1. These ingredients can be combined to form the basal animal cell culture medium which is then supplemented as described above with heparin, EGF, at least one agent increasing intracellular cAMP levels, at least one FGF and optionally with ascorbic acid, to formulate the complete media of the present invention.
- the concentration of a given ingredient can be increased or decreased beyond the range disclosed and the effect of the increased or decreased concentration can be determined using only routine experimentation.
- the concentrations of the ingredients of the medium of the present invention are the concentrations listed in the far right column of Table 1, supplemented with heparin, EGF, aFGF, isoproterenol and ascorbic acid as described above.
- each of the components of the culture medium may react with one or more other components in the solution.
- the present invention encompasses the formulations disclosed in Table 1, supplemented as described above, as well as any reaction mixture which forms after these ingredients are combined.
- the optimization of the present media formulations was carried out using approaches described by Ham (Ham, R.G., Methods for Preparation of Media, Supplements and Substrata or Serum-Free Animal Culture, Alan R. Liss, Inc., New York, pp. 3-21 (1984)) and Waymouth
- Cells which can be grown in the medium of the present invention are those of animal origin, including but not limited to cells obtained from mammals.
- Mammalian cells particularly suitable for cultivation in the present media include epithelial cells of human origin, which may be primary cells derived from a tissue sample such as keratinocytes, cervical epithelial cells, bronchial epithelial cells or tracheal epithelial cells, or transformed cells or established cell lines (e.g. , the HCAT human keratinocyte or HeLa cervical epithelial cell lines). These cells may be normal cells, or may optionally be diseased or genetically altered.
- mammalian cells such as CHO cells, COS cells, VERO cells, BHK cells (including BHK-21 cells) and derivatives thereof, are also suitable for cultivation in the present media.
- Particularly preferred are primary or secondary human keratinocytes derived from a sample of normal or abnormal human skin.
- Epithelial tissues, organs and organ systems derived from animals or constructed in vitro or in vivo using methods routine in the art may similarly be cultivated in the culture media of the present invention. Isolation of Cells
- Animal cells for culturing by the present invention may be obtained commercially, for example from ATCC (Rockville, Maryland), Cell Systems, Inc. (Kirkland, Washington), Clonetics
- cells may be isolated directly from samples of animal tissue obtained via biopsy, autopsy, donation or other surgical or medical procedure.
- Tissue should be handled using standard sterile technique and a laminar flow safety cabinet. In the use and processing of all human tissue, the recommendations of the U.S. Department of Health and Human Services/Centers for Disease Control and Prevention should be followed (Biosafety in Microbiological and Biomedical Laboratories, Richmond, IY. et al, Eds., U.S. Government Printing Office, Washington, D.C. 3rd Edition (1993)). The tissue should be cut into small pieces (e.g., 0.5 x 0.5 cm) using sterile surgical instruments.
- the small pieces should be washed twice with sterile saline solution supplemented with antibiotics as above, and then may be optionally treated with an enzymatic solution (e.g., collagenase or trypsin solutions, each available commercially, for example, from GIBCO/LTI, Gaithersburg, Maryland) to promote dissociation of cells from the tissue matrix.
- an enzymatic solution e.g., collagenase or trypsin solutions, each available commercially, for example, from GIBCO/LTI, Gaithersburg, Maryland
- the mixture of dissociated cells and matrix molecules are washed twice with a suitable physiological saline or tissue culture medium (e.g., Dulbecco's Phosphate Buffered Saline without calcium and magnesium). Between washes, the cells are centrifuged (e.g., at 200 xg) and then resuspended in serum-free tissue culture medium. Aliquots are counted using an electronic cell counter (such as a Coulter Counter). Alternatively, the cells can be counted manually using a hemocytometer.
- tissue culture medium e.g., Dulbecco's Phosphate Buffered Saline without calcium and magnesium.
- the isolated cells can be plated according to the experimental conditions determined by the investigator.
- the examples below demonstrate at least one functional set of culture conditions useful for cultivation of certain mammalian cells. It is to be understood, however, that the optimal plating and culture conditions for a given animal cell type can be determined by one of ordinary skill in the art using only routine experimentation.
- cells can be plated onto the surface of culture vessels without attachment factors.
- the vessels can be precoated with natural, recombinant or synthetic attachment factors or peptide fragments (e.g., collagen or fibronectin, or natural or synthetic fragments thereof).
- Isolated cells can also be seeded into or onto a natural or synthetic three- dimensional support matrix such as a preformed collagen gel or a synthetic biopolymeric material.
- a natural or synthetic three- dimensional support matrix such as a preformed collagen gel or a synthetic biopolymeric material.
- Use of attachment factors or a support matrix with the medium of the present invention will enhance cultivation of many attachment-dependent cells in the absence of serum supplementation.
- the cell seeding densities for each experimental condition can be optimized for the specific culture conditions being used. For routine culture in plastic culture vessels, an initial seeding density of 1-5 X 10 6 cells per cm 2 is preferable.
- Mammalian cells are typically cultivated in a cell incubator at about 37°C.
- the incubator atmosphere should be humidified and should contain about 3-10% carbon dioxide in air, although cultivation of certain cell lines may require as much as 20%> carbon dioxide in air for optimal results.
- Culture medium pH should be in the range of about 7.1-7.6, preferably about 7.1-7.4, and most preferably about 7.1-7.3.
- Cells in closed or batch culture should undergo complete medium exchange (i.e., replacing spent media with fresh media) about every 1-2 days, or more or less frequently as required by the specific cell type.
- Cells in perfusion culture e.g., in bioreactors or fermenters
- the cell culture media of the present invention may also be used to produce cell culture compositions comprising the present media and an animal epithelial cell.
- Animal epithelial cells which may be used to formulate the cell culture compositions of the present invention are those of animal origin, including but not limited to cells obtained from mammals.
- Mammalian cells particularly suitable for use in formulating the present cell culture compositions include epithelial cells of human origin, which may be primary cells derived from a tissue sample such as keratinocytes, cervical epithelial cells, bronchial epithelial cells or tracheal epithelial cells, or transformed cells or established cell lines (e.g., the HCAT human keratinocyte or HeLa cervical epithelial cell lines), or derivatives thereof.
- These cells may be normal cells, or may optionally be diseased or genetically altered.
- Other mammalian cells such as CHO cells, COS cells, VERO cells, BHK cells (including BHK-21 cells) and derivatives thereof, are also suitable for use in formulating the present cell culture compositions.
- Particularly preferred are primary or secondary human keratinocytes derived from a sample of normal or abnormal human skin.
- Epithelial tissues, organs and organ systems derived from animals or constructed in vitro or in vivo using methods routine in the art may similarly be used to formulate the cell culture compositions of the present invention.
- These cell culture compositions may be used in a variety of medical (including diagnostic and therapeutic), industrial, forensic and research applications requiring ready-to-use cultures of animal epithelial cells in serum-free media.
- GLBCO/LTI GLBCO/LTI
- Human neonatal foreskins were placed in serum-free medium (SFM) without growth factors containing 5 ⁇ g/ml gentamycin and were stored at 4°C.
- SFM serum-free medium
- Foreskins can be stored in this manner for about five days without significant loss of cell viability.
- Foreskins were briefly rinsed in 70% isopropanol and then placed into Dulbecco's phosphate-buffered saline (DPBS), without Ca ⁇ and Mg ⁇ , containing 20 ⁇ g/ml gentamycin for 60 minutes.
- DPBS Dulbecco's phosphate-buffered saline
- Foreskins were then cut into halves or quarters, depending upon the size of the tissue, and the pieces were transferred, dermis side down, to a petri dish containing 25 units/ml dispase, and were incubated 18-24 hours at 4°C.
- Epidermal sheets were separated from the full-thickness skin with forceps, pooled in 60 mm culture dishes containing 5-7 ml of 0.05% trypsin/0.53 mM EDTA, and were incubated at 37°C for 15-20 minutes with gentle pipetting to aid in tissue dissociation. Pooling of the tissue specimens is performed to reduce the effects of donor-to-donor growth variation. Trypsin activity was terminated by addition of soybean trypsin inhibitor (10 mg/ml in DPBS).
- Keratinocytes were plated at 2 X 10 4 cells/cm 2 in a total volume of 400 ⁇ l/0.8 cm 2 chamber. Cells were incubated for 24 hours, then fixed with 3.7% formaldehyde, permeabilized with 0.5% TRITON X-100 in DPBS, and allowed to react with rabbit anti-cytokeratin 14 antibody (1:200 dilution). Cells labeled with antibodies were visualized using goat anti-rabbit F(ab') 2 FITC conjugate (1:50 dilution).
- Human keratinocyte growth assays were performed in 24-well culture dishes (2 cm2 growth area) utilizing a seeding density of 1 x 10 4 cells/cm 2 . Endpoint growth assays were assessed at 6 days postseeding for primary cells and 72 hours for secondary cells. Growth kinetic assays were counted at 24 hour intervals over 96 hours without medium replacement. Single-cell cloning assays were performed in 96-well tissue culture-treated plates by serial dilution of cell suspensions to 5 cells/ml in the appropriate medium and plating 100 ⁇ l/well. Plates were incubated for 5 days before observation.
- media of the present invention were examined for their growth-promoting abilities relative to a defined human keratinocyte medium derived from Supplier A and to a BPE-containing formulation (Keratinocyte-SFM; GIBCO/LTI, Gaithersburg, Maryland).
- ddH 2 O deionized water
- L-alanine (9.00 mg/L), L-arginine ⁇ Cl (421.40 mg/L), L-asparagine»HCl (12.20 mg/L), L-aspartic acid (4.00 mg/L), L-cysteine»HCl»H 2 O (42.00 mg/L), L-glutamic acid (14.80 mg/L), L-glutamine (1020.00 mg/L), glycine (7.60 mg/L), L- histidine*HCl'H 2 O (50.40 mg/L), L-isoleucine (6.00 mg/L), L-leucine (131.20 mg/L), L- lysine ⁇ Cl (54.90 mg/L), L-methionine (13.50 mg/L), L-phenylalan
- a stock solution of phosphoethanolamine was prepared in ddH2O at 1408.00 mg/L and 0.1001 ml/L of this stock was added to the medium solution, to give a final concentration of phosphoethanolamine of 0.141 mg/L.
- a stock solution of FeSO 4 » 7H 2 O (41.70 mg/L), MgCl 2 «6H 2 O (18890 mg/L), and CaCl 2 » 2H 2 O (1344 mg L) was prepared in water containing 0.5 ml/L concentrated HC1, and 9.660 ml of this stock solution was added to the medium solution, to give final concentrations of 0.403 mg/L FeSO 4 » 7H 2 O, 182.48 mg/L MgCl 2 » 6H 2 O and 12.98 mg/L CaCl 2 »2H 2 O.
- a stock solution of ZnSO 4 » 7H 2 O (137.68 mg/L) was prepared in water, and 0.9660 ml of this solution was added to the medium solution to give a final concentration of 0.133 mg/L ZnSO 4 » 7H 2 O.
- a stock solution of hydrocortisone was prepared at 370 mg/L in 95% ethanol, and 0.2 ml of this stock was added to the medium solution to give a final concentration of hydrocortisone of 0.074 mg/L.
- T3 triiodothyronine
- NaHCOj (1160 mg/L) was added to the medium solution, and the pH of the solution was then adjusted with HCl to 7.2 ⁇ 0.05 and the volume adjusted to the full desired volume with ddH 2 O. The osmolality was determined to be 290 ⁇ 15 mOsm. This basal medium formulation was then filtered through a low protein-binding filter, bottled and stored under diminished light conditions at 4°C until use.
- DPBS Dulbecco's Phosphate Buffered Saline
- ascorbic acid phosphate, magnesium salt 50 mg/L
- aFGF 2.5 mg/L
- heparin 5000 units/L
- EGF 0.1 mg/L
- a stock solution of isoproterenol 100,000 mg/L was prepared in DPBS containing 50 mg/L ascorbic acid, and 1.25 ml/L of this solution was added to the above, to form a 500X formulation of the growth supplement.
- This 500X solution was then filtered through a low protein-binding filter, and added to the basal medium or aliquotted and stored at -20 to -80 °C until use in epithelial cell culture medium as a replacement for an organ or gland extract such as BPE.
- the basal medium containing heparin, EGF and aFGF from Example 2 was examined with and without the addition of 0.25 mg/L isoproterenol.
- Primary human keratinocytes were isolated and cultured as described for Example 2. Representative results of five separate experiments, comparing growth in the medium with and without isoproterenol to that in a BPE-containing keratinocyte SFM ("control") are shown in Table 3.
- compositions comprising heparin, EGF, FGF and a cAMP-activating agent such as isoproterenol may be used as a replacement for an organ or gland extract such as BPE in SFM for the culture of epithelial cells such as keratinocytes.
- a defined medium comprising the basal medium, heparin, EGF, aFGF and isoproterenol, and optionally including ascorbic acid
- a solution comprising heparin, EGF, FGF, a cAMP- increasing agent such as isoproterenol and ascorbic acid may be used as a replacement for an organ or gland extract such as BPE in SFM for the culture of epithelial cells such as keratinocytes.
- the defined serum-free medium of the present invention supports the growth of primary human keratinocytes, and outperforms even undefined, traditionally used BPE-containing media.
- the defined serum-free medium of the present invention supports the growth of primary and secondary human keratinocytes, and outperforms both undefined BPE-containing media and at least one other defined media currently available commercially.
- the fully supplemented defined SFM of the present invention had a shelf life of over 14 weeks, which was considerably longer than the BPE-containing medium.
- Examples 1-6 indicate that an optimal culture medium formulation for supporting the cultivation of animal cells is the basal medium formulation shown in Table 1, supplemented with EGF at about 5-10 mg/Liter, aFGF at about 5 mg/Liter, isoproterenol at about 0.3 mg/Liter and ascorbic acid at about 50 mg/Liter (although ascorbic acid may be eliminated with only a slight diminution of growth promotion).
Landscapes
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69737455T DE69737455T2 (en) | 1996-10-11 | 1997-10-09 | DEFINED SYSTEMS FOR CULTURING EPITHELIAL CELLS AND APPLYING THE SAME |
AU47517/97A AU4751797A (en) | 1996-10-11 | 1997-10-09 | Defined systems for epithelial cell culture and use thereof |
EP97910044A EP0939797B1 (en) | 1996-10-11 | 1997-10-09 | Defined systems for epithelial cell culture and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2847196P | 1996-10-11 | 1996-10-11 | |
US60/028,471 | 1996-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998016629A1 true WO1998016629A1 (en) | 1998-04-23 |
Family
ID=21843633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/018260 WO1998016629A1 (en) | 1996-10-11 | 1997-10-09 | Defined systems for epithelial cell culture and use thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0939797B1 (en) |
AT (1) | ATE356198T1 (en) |
AU (1) | AU4751797A (en) |
DE (1) | DE69737455T2 (en) |
WO (1) | WO1998016629A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000002999A2 (en) * | 1998-07-10 | 2000-01-20 | Encelle, Inc. | Medium and matrix for long-term proliferation of cells |
WO2001003726A1 (en) * | 1999-07-13 | 2001-01-18 | Biovitrum Ab | Stable factor viii compositions |
WO2001018175A1 (en) * | 1999-09-03 | 2001-03-15 | Applied Research Systems Ars Holding N.V. | Method for producing a heterologous secreted protein from chinese hamster ovary cells grown on microcarriers |
US6224860B1 (en) | 1996-10-18 | 2001-05-01 | Quality Biological, Inc. | Method for repopulating human bone marrow comprising culturing CD34+ cells in a serum free medium |
US6352707B1 (en) | 1992-02-24 | 2002-03-05 | Anton-Lewis Usala | Transplant encapsulation in a hydrogel matrix to obscure immune recognition |
WO2003055990A2 (en) * | 2001-12-21 | 2003-07-10 | Pharmagap Inc. | Method for culturing and expansion of mammalian undifferentiated epidermal keratinocytes exhibiting stem cell characteristics |
EP1360314A2 (en) * | 2001-02-15 | 2003-11-12 | Centocor, Inc. | Chemically defined medium for cultured mammalian cells |
EP1609462A1 (en) * | 2004-04-22 | 2005-12-28 | JUVENA (International) AG | Cosmetic or dermatological preparation comprising a nutrient medium phase |
EP1754784A2 (en) * | 1999-09-03 | 2007-02-21 | Applied Research Systems ARS Holding N.V. | Method for producing a heterologous secreted protein from chinese hamster ovary cells grown on microcarriers |
US8518422B2 (en) | 2003-05-24 | 2013-08-27 | La Prairie Group Ag | Cosmetic or dermatological preparation comprising a nutrient medium phase |
CN113667632A (en) * | 2021-09-14 | 2021-11-19 | 上海艾济生物科技有限公司 | Cell culture medium additive, cell culture medium and method for in vitro cell amplification |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4533637A (en) * | 1981-05-28 | 1985-08-06 | Ajinomoto Co., Inc. | Culture medium |
EP0531733A1 (en) * | 1991-08-12 | 1993-03-17 | Biomaterial Co., Ltd. | Carrier for animal cell culture |
US5292655A (en) * | 1990-01-29 | 1994-03-08 | Wille Jr John J | Method for the formation of a histologically-complete skin substitute |
US5342777A (en) * | 1988-12-14 | 1994-08-30 | The United States Of America As Represented By The Secretary Of The Dept. Of Health And Human Services | Cell culture medium for human liver epithelial cell line |
US5364785A (en) * | 1990-02-09 | 1994-11-15 | Genentech, Inc. | Method of isolating lung cell line |
US5461030A (en) * | 1991-02-01 | 1995-10-24 | Life Medical Science, Inc. | Compositions and methods for enhancing wound healing |
-
1997
- 1997-10-09 DE DE69737455T patent/DE69737455T2/en not_active Expired - Lifetime
- 1997-10-09 WO PCT/US1997/018260 patent/WO1998016629A1/en active IP Right Grant
- 1997-10-09 EP EP97910044A patent/EP0939797B1/en not_active Expired - Lifetime
- 1997-10-09 AT AT97910044T patent/ATE356198T1/en not_active IP Right Cessation
- 1997-10-09 AU AU47517/97A patent/AU4751797A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4533637A (en) * | 1981-05-28 | 1985-08-06 | Ajinomoto Co., Inc. | Culture medium |
US5342777A (en) * | 1988-12-14 | 1994-08-30 | The United States Of America As Represented By The Secretary Of The Dept. Of Health And Human Services | Cell culture medium for human liver epithelial cell line |
US5292655A (en) * | 1990-01-29 | 1994-03-08 | Wille Jr John J | Method for the formation of a histologically-complete skin substitute |
US5364785A (en) * | 1990-02-09 | 1994-11-15 | Genentech, Inc. | Method of isolating lung cell line |
US5461030A (en) * | 1991-02-01 | 1995-10-24 | Life Medical Science, Inc. | Compositions and methods for enhancing wound healing |
EP0531733A1 (en) * | 1991-08-12 | 1993-03-17 | Biomaterial Co., Ltd. | Carrier for animal cell culture |
Non-Patent Citations (6)
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6231881B1 (en) | 1992-02-24 | 2001-05-15 | Anton-Lewis Usala | Medium and matrix for long-term proliferation of cells |
US6730315B2 (en) | 1992-02-24 | 2004-05-04 | Encelle, Inc. | Medium and matrix for long-term proliferation of cells |
US6713079B2 (en) | 1992-02-24 | 2004-03-30 | Encelle, Inc. | Methods for increasing vascularization and promoting wound healing |
US6352707B1 (en) | 1992-02-24 | 2002-03-05 | Anton-Lewis Usala | Transplant encapsulation in a hydrogel matrix to obscure immune recognition |
US6315994B2 (en) | 1992-02-24 | 2001-11-13 | Anton-Lewis Usala | Medium and matrix for long-term proliferation of cells |
US6224860B1 (en) | 1996-10-18 | 2001-05-01 | Quality Biological, Inc. | Method for repopulating human bone marrow comprising culturing CD34+ cells in a serum free medium |
US6372210B2 (en) | 1996-10-18 | 2002-04-16 | Quality Biological, Inc. | Method for repopulating human bone marrow comprising culturing CD34+ cells in a serum free medium |
US6261587B1 (en) | 1998-07-10 | 2001-07-17 | Anton-Lewis Usala | Methods for increasing vascularization and promoting wound healing |
WO2000002999A2 (en) * | 1998-07-10 | 2000-01-20 | Encelle, Inc. | Medium and matrix for long-term proliferation of cells |
WO2000002999A3 (en) * | 1998-07-10 | 2000-04-20 | Encelle Inc | Medium and matrix for long-term proliferation of cells |
JP2003504345A (en) * | 1999-07-13 | 2003-02-04 | ビオヴィトルム・アクチボラゲット | Stable factor VIII composition |
JP4674021B2 (en) * | 1999-07-13 | 2011-04-20 | ビオヴィトルム・アクチボラゲット(プブリクト) | Stable factor VIII composition |
US6599724B1 (en) | 1999-07-13 | 2003-07-29 | Biovitrum Ab | Stable factor VIII compositions |
WO2001003726A1 (en) * | 1999-07-13 | 2001-01-18 | Biovitrum Ab | Stable factor viii compositions |
WO2001018175A1 (en) * | 1999-09-03 | 2001-03-15 | Applied Research Systems Ars Holding N.V. | Method for producing a heterologous secreted protein from chinese hamster ovary cells grown on microcarriers |
US6458565B1 (en) | 1999-09-03 | 2002-10-01 | Applied Research Systems Ars Holding N.V. | Method for producing a heterologous secreted protein from chinese hamster ovary cells grown on microcarriers |
EP1754784A3 (en) * | 1999-09-03 | 2007-02-28 | Applied Research Systems ARS Holding N.V. | Method for producing a heterologous secreted protein from chinese hamster ovary cells grown on microcarriers |
EP1754784A2 (en) * | 1999-09-03 | 2007-02-21 | Applied Research Systems ARS Holding N.V. | Method for producing a heterologous secreted protein from chinese hamster ovary cells grown on microcarriers |
EP1360314A4 (en) * | 2001-02-15 | 2004-08-11 | Centocor Inc | Chemically defined medium for cultured mammalian cells |
EP1360314A2 (en) * | 2001-02-15 | 2003-11-12 | Centocor, Inc. | Chemically defined medium for cultured mammalian cells |
WO2003055990A3 (en) * | 2001-12-21 | 2003-10-09 | Pharmagap Inc | Method for culturing and expansion of mammalian undifferentiated epidermal keratinocytes exhibiting stem cell characteristics |
WO2003055990A2 (en) * | 2001-12-21 | 2003-07-10 | Pharmagap Inc. | Method for culturing and expansion of mammalian undifferentiated epidermal keratinocytes exhibiting stem cell characteristics |
US8518422B2 (en) | 2003-05-24 | 2013-08-27 | La Prairie Group Ag | Cosmetic or dermatological preparation comprising a nutrient medium phase |
EP1609462A1 (en) * | 2004-04-22 | 2005-12-28 | JUVENA (International) AG | Cosmetic or dermatological preparation comprising a nutrient medium phase |
CN113667632A (en) * | 2021-09-14 | 2021-11-19 | 上海艾济生物科技有限公司 | Cell culture medium additive, cell culture medium and method for in vitro cell amplification |
CN113667632B (en) * | 2021-09-14 | 2023-10-17 | 上海艾济生物科技有限公司 | Cell culture medium additive, cell culture medium and method for in-vitro cell expansion |
Also Published As
Publication number | Publication date |
---|---|
EP0939797B1 (en) | 2007-03-07 |
DE69737455T2 (en) | 2007-12-06 |
ATE356198T1 (en) | 2007-03-15 |
EP0939797A4 (en) | 2004-04-28 |
AU4751797A (en) | 1998-05-11 |
DE69737455D1 (en) | 2007-04-19 |
EP0939797A1 (en) | 1999-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6692961B1 (en) | Defined systems for epithelial cell culture and use thereof | |
AU621972B2 (en) | Cell culture medium for human liver epithelial cell line | |
Hammond et al. | Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. | |
JP2577114B2 (en) | Cell culture media | |
US6103529A (en) | Animal cell culture media comprising peptides derived from rice | |
JP2002529071A (en) | Serum-free medium for chondrocyte-like cells | |
WO2007117565A9 (en) | Standardization of processes for culturing primary cells | |
KR20060076781A (en) | Cell culture media | |
US20110183375A1 (en) | Metal binding compounds and their use in cell culture medium compositions | |
EP1937798A1 (en) | Chemically defined culture media for expansion and differentiation of epidermal cells and uses thereof for in vitro growth of hair follicles | |
EP0939797B1 (en) | Defined systems for epithelial cell culture and use thereof | |
EP1210410B1 (en) | Metal binding compounds and their use in cell culture medium compositions | |
AU756151B2 (en) | Immortalised cell lines derived from normal human skin tissues | |
US20050019310A1 (en) | Method for culturing and expansion of mammalian undifferentiated epidermal kerainocytes exhibiting stem cell characteristics | |
US6008047A (en) | Cell culturing method and medium | |
Insler et al. | Microcarrier cell culture of neonatal human corneal endothelium | |
Sime et al. | Method for the growth of equine airway epithelial cells in culture | |
Denk et al. | Serum-free cultivation of human Tenon’s capsule fibroblasts | |
EP1059352A1 (en) | Long term cell culture of human carcinoma | |
KR100567655B1 (en) | A medium for culturing a fibroblast, a method of producing a dermis equivalent using the medium and a dermis equivalent produced by the method, a method of producing a skin equivalent using the dermis equivalent and a skin equivalent produced by the method | |
EP3554487A1 (en) | Xenobiotic-free culture system to expand human limbal stem cells | |
Wise et al. | Normal human bronchial epithelial cell culture | |
US20030104613A1 (en) | Method for producing adherent animal cells | |
CN114317429A (en) | Composition and application thereof in stem cell culture | |
JP2577114C (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997910044 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997910044 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997910044 Country of ref document: EP |